Four industry-level analyses

These four analyses cover: Research & Development for people in low- and middle-income countries; Product Deployment, using pricing, licensing and donations; Governance & Compliance, and how closer integration of these policy areas can benefit access to medicine; and whether companies match Capacity Building activities to local priorities.

Leaders In R&D Address Needs And Ensure Access For People Living In Low- And  Middle-income Countries.

Leaders in R&D address needs and ensure access for people living in low- and middle-income countries.

Many new health products are urgently needed – particularly for people in low- and middle-income countries. The Access to Medicine Index assesses companies’ efforts to engage in R&D for 51 diseases and conditions that have the greatest burdens in low- and middle- income countries and the greatest need in terms of access to medicine.
Continue reading
Companies Use A Mix Of Tools To Address Availability And Affordability, Yet Good Practices Extend To Only A Few Products And Diseases. Companies Do Not Consistently Include Poor Populations In Registration, Pricing And Licensing Actions.

Companies use a mix of tools to address availability and affordability, yet good practices extend to only a few products and diseases. Companies do not consistently include poor populations in registration, pricing and licensing actions.

This chapter analyses pharmaceutical product deployment: how pharmaceutical companies ensure their products reach the people who need them. As a first step, companies must register their products in countries where they are needed.
Continue reading
Pharmaceutical Companies Continue To Refine Their Approaches For Increasing Access To Medicine. Yet Poor Compliance Risks Undermining These Investments.

Pharmaceutical companies continue to refine their approaches for increasing access to medicine. Yet poor compliance risks undermining these investments.

Governance and compliance are two pillars of corporate management. They enable companies to achieve strategic goals in an efficient, ethical and transparent manner. Failure of these systems, however, can lead to corruption. Its consequences can include the diversion of public funds away from essential healthcare, or the over- or wrongful prescription and use of medicines.
Continue reading
Leaders Consistently Target Local Needs  Through Best Practice Approaches To Capacity Building

Leaders consistently target local needs through best practice approaches to capacity building

The pharmaceutical industry has an important role and an interest in supporting low- and middle-income countries to strengthen local health systems. To maximise the impact on access to medicine and to prevent conflicts of interest, companies’ activities must respond to local needs. This is more than good practice: it is a minimum requirement.
Continue reading

Sign up to receive updates about our work.